ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional Results available

A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

ClinicalTrials.gov ID: NCT03431350

Public ClinicalTrials.gov record NCT03431350. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Study identification

NCT ID
NCT03431350
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Janssen Research & Development, LLC
Industry
Enrollment
136 participants

Conditions and interventions

Interventions

  • Abiraterone acetate 1000 mg Drug
  • Cetrelimab 240 mg Drug
  • Cetrelimab 480 mg Drug
  • Niraparib 200 mg Drug
  • Prednisone 5 mg Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 1, 2018
Primary completion
Aug 30, 2021
Completion
Dec 30, 2026
Last update posted
Apr 12, 2026

2018 – 2026

United States locations

U.S. sites
19
U.S. states
14
U.S. cities
18
Facility City State ZIP Site status
Urological Associates of Southern Arizona, P.C. Tucson Arizona 85741
The Urology Center of Colorado Denver Colorado 80211
Mayo Clinic - Division Of Hematology/oncology Jacksonville Florida 32224
First Urology, PSC Jeffersonville Indiana 47130
Chesapeake Urology Research Associates Towson Maryland 21204
Michigan Institute of Urology Troy Michigan 48084
New York Oncology Hematology Albany New York 12208
Memorial Sloan Kettering Cancer Center 1 Harrison New York 10604
Memorial Sloan Kettering Cancer Center New York New York 10065
Thomas Jefferson University Philadelphia Pennsylvania 19107
University of Pittsburgh Medical Center (UPMC) Pittsburgh Pennsylvania 15232
MUSC-Hollings Cancer Center Charleston South Carolina 29425
Carolina Urologic Research Center Myrtle Beach South Carolina 29572
Urology Associates Nashville Tennessee 37209
Houston Metro Urology Houston Texas 77027
The University of Texas MD Anderson Cancer Center Houston Texas 77030
Utah Cancer Specialists Salt Lake City Utah 84106
Urology of Virginia, PLCC Virginia Beach Virginia 23462
University of Wisconsin Carbone Cancer Center Madison Wisconsin 5379200

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03431350, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 12, 2026 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03431350 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →